https://www.pharmaceutical-technology.com/data-insights/pimicotinib-abbisko-therapeutics-tenosynovial-giant-cell-tumor-likelihood-of-approval/ 2024-07-05T17:48:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimicotinib-abbisko-therapeutics-solid-tumor-likelihood-of-approval/ 2024-07-05T17:48:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimicotinib-abbisko-therapeutics-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-04T19:57:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimicotinib-abbisko-therapeutics-advanced-malignancy-likelihood-of-approval/ 2024-01-04T19:56:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/descartes-11-cartesian-therapeutics-refractory-multiple-myeloma-likelihood-of-approval/ 2024-02-22T01:06:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/descartes-11-cartesian-therapeutics-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-02-22T01:06:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/scb-1019-clover-biopharmaceuticals-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-05-20T04:10:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bat-4406f-bio-thera-solutions-autoimmune-disorders-likelihood-of-approval/ 2024-09-09T04:56:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexmedetomidine-bioxcel-therapeutics-alcohol-dependence-likelihood-of-approval/ 2025-01-21T01:09:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dexmedetomidine-bioxcel-therapeutics-post-traumatic-stress-disorder-ptsd-likelihood-of-approval/ 2025-01-21T01:09:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fb-849-1st-bio-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-20T01:11:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-cart-19-1-miltenyi-biomedicine-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:08:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-cart-19-1-miltenyi-biomedicine-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:08:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-cart-19-1-miltenyi-biomedicine-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T01:08:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-cart-19-1-miltenyi-biomedicine-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:08:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tarlatamab-amgen-small-cell-lung-cancer-likelihood-of-approval/ 2024-06-19T05:56:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/monoclonal-antibody-to-target-cd20-for-non-hodgkin-lymphoma-shenzhen-salubris-pharmaceuticals-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:56:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hbv-tcr-t-cell-therapy-lion-tcr-hepatitis-b-likelihood-of-approval/ 2024-05-20T04:10:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atropine-sulfate-vyluma-myopia-likelihood-of-approval/ 2024-01-24T19:29:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imvotamab-igm-biosciences-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:56:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tumorad-spago-nanomedical-breast-cancer-likelihood-of-approval/ 2024-01-24T19:29:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:56:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:08:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T01:08:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-burkitt-lymphoma-likelihood-of-approval/ 2024-09-09T04:55:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-106-mustang-bio-mantle-cell-lymphoma-likelihood-of-approval/ 2024-01-04T19:50:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/u-01-shanghai-unicar-therapy-bio-medicine-technology-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-07-05T17:48:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/u-01-shanghai-unicar-therapy-bio-medicine-technology-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:08:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/u-01-shanghai-unicar-therapy-bio-medicine-technology-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:08:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/riliprubart-sanofi-acquired-autoimmune-hemolytic-anemia-likelihood-of-approval/ 2024-01-04T18:34:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/riliprubart-sanofi-polyradiculoneuropathy-likelihood-of-approval/ 2024-01-24T19:29:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tonabersat-inflammx-therapeutics-wet-neovascular-exudative-macular-degeneration-likelihood-of-approval/ 2025-01-21T01:08:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/riliprubart-sanofi-chronic-inflammatory-demyelinating-polyneuropathy-cidp-likelihood-of-approval/ 2025-01-21T01:08:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tonabersat-inflammx-therapeutics-diabetic-nephropathy-likelihood-of-approval/ 2025-01-21T01:08:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tonabersat-inflammx-therapeutics-dry-atrophic-macular-degeneration-likelihood-of-approval/ 2025-01-21T01:08:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obi-999-obi-pharma-esophageal-cancer-likelihood-of-approval/ 2024-01-04T18:33:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tonabersat-inflammx-therapeutics-diabetic-macular-edema-likelihood-of-approval/ 2025-01-21T01:08:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obi-999-obi-pharma-gastric-cancer-likelihood-of-approval/ 2024-01-04T18:32:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obi-999-obi-pharma-solid-tumor-likelihood-of-approval/ 2024-01-04T18:32:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obi-999-obi-pharma-colorectal-cancer-likelihood-of-approval/ 2024-01-04T18:32:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obi-999-obi-pharma-pancreatic-cancer-likelihood-of-approval/ 2024-01-04T18:32:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biosimilar-apotex-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T04:55:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/modakafusp-alfa-takeda-pharmaceutical-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2024-09-09T04:55:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitocabnagene-loxiveluecel-takeda-pharmaceutical-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:55:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biosimilar-apotex-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:55:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitocabnagene-loxiveluecel-takeda-pharmaceutical-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:55:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitocabnagene-loxiveluecel-takeda-pharmaceutical-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-06-19T05:55:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitocabnagene-loxiveluecel-takeda-pharmaceutical-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-06-19T05:55:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitocabnagene-loxiveluecel-takeda-pharmaceutical-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-06-19T05:55:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitocabnagene-loxiveluecel-takeda-pharmaceutical-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-06-19T05:55:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitocabnagene-loxiveluecel-takeda-pharmaceutical-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-06-19T05:55:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitocabnagene-loxiveluecel-takeda-pharmaceutical-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-01-24T19:28:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitocabnagene-loxiveluecel-takeda-pharmaceutical-follicular-lymphoma-likelihood-of-approval/ 2024-01-24T19:28:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kur-502-athenex-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-05-20T04:09:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sitocabnagene-loxiveluecel-takeda-pharmaceutical-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-06-19T05:55:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvilostomig-systimmune-gastrointestinal-tumor-likelihood-of-approval/ 2025-01-21T01:08:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kur-502-athenex-b-cell-chronic-lymphocytic-leukemia-likelihood-of-approval/ 2024-05-20T04:09:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvilostomig-systimmune-esophageal-cancer-likelihood-of-approval/ 2025-01-21T01:07:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvilostomig-systimmune-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:07:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mb-105-mustang-bio-pancreatic-cancer-likelihood-of-approval/ 2024-04-20T01:10:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/survodutide-boehringer-ingelheim-international-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-21T01:07:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/survodutide-boehringer-ingelheim-international-liver-fibrosis-likelihood-of-approval/ 2025-01-21T01:07:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zamtocabtagene-autoleucel-miltenyi-biomedicine-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-01-04T18:25:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aom-0765-hangzhou-adamerck-pharmlabs-anesthetic-effect-likelihood-of-approval/ 2024-01-04T18:25:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zamtocabtagene-autoleucel-miltenyi-biomedicine-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T01:07:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zamtocabtagene-autoleucel-miltenyi-biomedicine-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T01:07:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zamtocabtagene-autoleucel-miltenyi-biomedicine-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:07:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zamtocabtagene-autoleucel-miltenyi-biomedicine-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:07:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-acute-lymphocytic-leukemia-and-follicular-lymphoma-shenzhen-bindebio-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-06-19T05:55:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zamtocabtagene-autoleucel-miltenyi-biomedicine-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-09-09T04:55:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-19-beijing-immunochina-pharmaceuticals-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:55:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-acute-lymphocytic-leukemia-and-follicular-lymphoma-shenzhen-bindebio-follicular-lymphoma-likelihood-of-approval/ 2024-06-19T05:55:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-19-beijing-immunochina-pharmaceuticals-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:55:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-19-beijing-immunochina-pharmaceuticals-follicular-lymphoma-likelihood-of-approval/ 2024-02-22T01:05:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-19-beijing-immunochina-pharmaceuticals-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-09-09T04:55:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/im-19-beijing-immunochina-pharmaceuticals-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:55:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/senl-002-hebei-senlang-biotechnology-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-01-04T18:21:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosgonimeton-athira-pharma-parkinson-s-disease-likelihood-of-approval/ 2024-06-19T05:54:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosgonimeton-athira-pharma-lewy-body-dementia-likelihood-of-approval/ 2024-06-19T05:54:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cp-101-finch-therapeutics-group-ulcerative-colitis-likelihood-of-approval/ 2024-01-04T18:20:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fosgonimeton-athira-pharma-dementia-likelihood-of-approval/ 2025-01-21T01:07:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-lymphoma-sinobioway-cell-therapy-lymphoma-likelihood-of-approval/ 2024-04-20T01:10:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986218-bristol-myers-squibb-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-06-19T05:54:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-0508-ctx-operations-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-02-08T04:31:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-0508-ctx-operations-salivary-gland-cancer-likelihood-of-approval/ 2024-02-08T04:31:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nlg-802-lumos-pharma-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-01-04T18:18:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vxx-001-viravaxx-hepatitis-b-likelihood-of-approval/ 2024-01-04T18:18:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aurixim-biointegrator-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-01-04T18:17:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aurixim-biointegrator-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-01-04T18:17:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aurixim-biointegrator-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-01-04T18:17:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aurixim-biointegrator-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-01-04T18:17:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aurixim-biointegrator-follicular-lymphoma-likelihood-of-approval/ 2024-01-04T18:16:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/aurixim-biointegrator-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2024-01-04T18:16:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/io-102-io-103-io-biotech-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-21T01:07:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ccar-039-janssen-biotech-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-05-20T04:08:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/io-102-io-103-io-biotech-laryngeal-cancer-likelihood-of-approval/ 2025-01-21T01:07:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/io-102-io-103-io-biotech-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:07:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/io-102-io-103-io-biotech-melanoma-likelihood-of-approval/ 2025-01-21T01:07:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/io-102-io-103-io-biotech-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-21T01:07:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-oncology-and-immunology-shanghai-genechem-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-01-04T18:14:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:06:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2025-01-21T01:07:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T01:06:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:06:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:06:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ic9-car-19-bellicum-pharmaceuticals-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:06:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daplusiran-johnson-johnson-hepatitis-b-likelihood-of-approval/ 2024-01-04T18:12:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inavolisib-genentech-usa-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-04-20T01:10:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acrixolimab-y-biologics-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-21T01:06:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acrixolimab-y-biologics-thyroid-cancer-likelihood-of-approval/ 2025-01-21T01:06:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-21T01:06:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/syd-4228-byondis-mantle-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:55:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:06:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-21T01:06:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-follicular-lymphoma-likelihood-of-approval/ 2024-04-20T01:10:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-primary-cns-lymphoma-likelihood-of-approval/ 2025-01-21T01:06:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-04-20T01:10:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-mantle-cell-lymphoma-likelihood-of-approval/ 2024-04-20T01:10:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trph-222-triphase-accelerator-follicular-lymphoma-likelihood-of-approval/ 2024-03-19T00:19:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obecabtagene-autoleucel-autolus-therapeutics-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:06:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trph-222-triphase-accelerator-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-03-19T00:19:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trph-222-triphase-accelerator-mantle-cell-lymphoma-likelihood-of-approval/ 2024-03-19T00:19:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esepapogene-zalarnarepvec-hookipa-pharma-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T01:06:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trph-222-triphase-accelerator-lymphoma-likelihood-of-approval/ 2024-01-04T18:07:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tilt-123-tilt-biotherapeutics-melanoma-likelihood-of-approval/ 2025-01-21T01:05:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/esepapogene-zalarnarepvec-hookipa-pharma-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-21T01:05:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/masct-hengrui-yuanzheng-biotechnology-bone-sarcoma-likelihood-of-approval/ 2025-01-21T01:05:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/palopegteriparatide-ascendis-pharma-hypoparathyroidism-likelihood-of-approval/ 2024-09-09T04:54:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tifcemalimab-shanghai-junshi-biosciences-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T01:05:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/san-711-saniona-epilepsy-likelihood-of-approval/ 2024-05-20T04:07:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/budigalimab-abbvie-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-21T01:05:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/apinocaltamide-neurocrine-biosciences-epileptic-encephalopathy-likelihood-of-approval/ 2024-06-19T05:54:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pivekimab-sunirine-immunogen-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T01:05:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/budigalimab-abbvie-solid-tumor-likelihood-of-approval/ 2025-01-21T01:05:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-21T01:05:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rosnilimab-anaptysbio-ulcerative-colitis-likelihood-of-approval/ 2025-01-21T01:05:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0486-astrazeneca-follicular-lymphoma-likelihood-of-approval/ 2025-01-21T01:05:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0486-astrazeneca-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T01:05:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/at-101-abclon-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-04-20T01:09:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-0486-astrazeneca-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:05:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-21T01:05:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-bladder-cancer-likelihood-of-approval/ 2025-01-21T01:05:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-salivary-gland-cancer-likelihood-of-approval/ 2025-01-21T01:05:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-breast-cancer-likelihood-of-approval/ 2024-02-08T04:30:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/disitamab-vedotin-pfizer-cervical-cancer-likelihood-of-approval/ 2025-01-21T01:04:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-rapt-therapeutics-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2024-04-20T01:09:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afamitresgene-autoleucel-adaptimmune-therapeutics-synovial-sarcoma-likelihood-of-approval/ 2024-09-09T04:54:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-rapt-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-04-20T01:09:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-rapt-therapeutics-esophageal-cancer-likelihood-of-approval/ 2024-04-20T01:09:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-rapt-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-04-20T01:08:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-rapt-therapeutics-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2024-04-20T01:08:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenretinide-scitech-development-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-21T01:04:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tivumecirnon-rapt-therapeutics-cervical-cancer-likelihood-of-approval/ 2024-04-20T01:08:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenretinide-scitech-development-mycosis-fungoides-likelihood-of-approval/ 2025-01-21T01:04:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenretinide-scitech-development-anaplastic-large-cell-lymphoma-alcl-likelihood-of-approval/ 2025-01-21T01:04:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenretinide-scitech-development-sezary-syndrome-likelihood-of-approval/ 2025-01-21T01:04:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenretinide-scitech-development-angioimmunoblastic-t-cell-lymphoma-aitl-immunoblastic-lymphadenopathy-likelihood-of-approval/ 2025-01-21T01:04:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ft-819-fate-therapeutics-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-04-20T01:08:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fenretinide-scitech-development-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:04:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/b-001-shanghai-pharmaceutical-group-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-01-04T17:55:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ft-819-fate-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:54:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azercabtagene-zapreleucel-imugene-follicular-lymphoma-likelihood-of-approval/ 2024-04-20T01:08:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azercabtagene-zapreleucel-imugene-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-04-20T01:08:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azercabtagene-zapreleucel-imugene-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-04-20T01:08:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azercabtagene-zapreleucel-imugene-mantle-cell-lymphoma-likelihood-of-approval/ 2024-04-20T01:08:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-07-22T13:57:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-starlight-therapeutics-high-grade-glioma-likelihood-of-approval/ 2024-07-05T17:46:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-starlight-therapeutics-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-07-05T17:46:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-bladder-cancer-likelihood-of-approval/ 2025-01-21T01:04:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-starlight-therapeutics-central-nervous-system-cns-cancer-likelihood-of-approval/ 2024-09-09T04:54:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-melanoma-likelihood-of-approval/ 2024-07-22T13:58:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-liver-cancer-likelihood-of-approval/ 2024-09-09T04:54:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-prostate-cancer-likelihood-of-approval/ 2025-01-21T01:04:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:04:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-lung-cancer-likelihood-of-approval/ 2025-01-21T01:04:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-ovarian-cancer-likelihood-of-approval/ 2025-01-21T01:04:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/safusidenib-anheart-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-20T01:07:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/safusidenib-anheart-therapeutics-bile-duct-cancer-cholangiocarcinoma-likelihood-of-approval/ 2024-04-20T01:07:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bnt-312-biontech-pancreatic-cancer-likelihood-of-approval/ 2024-01-04T17:49:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bersacapavir-johnson-johnson-hepatitis-b-likelihood-of-approval/ 2025-01-21T01:04:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/edp-938-enanta-pharmaceuticals-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-01-04T17:49:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gotistobart-oncoc4-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-21T01:04:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hepalatide-shanghai-hep-pharmaceutical-hepatitis-b-likelihood-of-approval/ 2024-07-05T17:45:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hepalatide-shanghai-hep-pharmaceutical-hepatitis-d-likelihood-of-approval/ 2024-07-05T17:45:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cnmau-8-clene-relapsing-multiple-sclerosis-rms-likelihood-of-approval/ 2025-01-21T01:04:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asundexian-bayer-myocardial-infarction-likelihood-of-approval/ 2024-01-04T17:48:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ba-3071-bioatla-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2024-01-04T17:47:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ba-3071-bioatla-uveal-melanoma-likelihood-of-approval/ 2024-01-04T17:47:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-05T17:45:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-07-05T17:45:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-fibrosarcoma-likelihood-of-approval/ 2024-07-05T17:45:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-bladder-carcinoma-likelihood-of-approval/ 2024-07-05T17:45:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-rhabdomyosarcoma-likelihood-of-approval/ 2024-07-05T17:45:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-thymic-carcinoma-likelihood-of-approval/ 2024-07-05T17:45:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2024-07-05T17:45:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-esophageal-cancer-likelihood-of-approval/ 2024-07-05T17:45:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T17:45:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bintrafusp-alfa-merck-melanoma-likelihood-of-approval/ 2025-01-21T01:03:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/palivizumab-biosimilar-mabxience-holding-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2025-01-21T01:03:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yson-001-yisheng-biopharma-metastatic-breast-cancer-likelihood-of-approval/ 2024-04-20T01:07:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yson-001-yisheng-biopharma-metastatic-liver-cancer-likelihood-of-approval/ 2024-04-20T01:07:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-zovodotin-zymeworks-colorectal-cancer-likelihood-of-approval/ 2024-07-05T17:45:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanidatamab-zovodotin-zymeworks-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-07-05T17:45:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-3-autolus-therapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2024-01-04T17:42:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-3-autolus-therapeutics-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-05-20T04:06:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adct-602-adc-therapeutics-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-01-04T17:41:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/auto-3-autolus-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-01-04T17:41:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plamotamab-xencor-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T01:03:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/liraglutide-biobetter-biolingus-obesity-likelihood-of-approval/ 2025-01-21T01:03:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mosunetuzumab-genentech-usa-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T01:03:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-2-for-oncology-alaunos-therapeutics-leukemia-likelihood-of-approval/ 2024-04-20T01:06:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmn-005-coimmune-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-09-09T04:53:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-b-cell-malignancies-alaunos-therapeutics-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2024-04-20T01:06:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-2-for-oncology-alaunos-therapeutics-lymphoma-likelihood-of-approval/ 2024-04-20T01:06:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-b-cell-malignancies-alaunos-therapeutics-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-04-20T01:06:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gene-therapy-to-target-cd19-for-b-cell-malignancies-alaunos-therapeutics-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-04-20T01:06:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bpx-401-bellicum-pharmaceuticals-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-09-09T04:53:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nedisertib-merck-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-20T01:06:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nedisertib-merck-neuroendocrine-tumors-likelihood-of-approval/ 2025-01-21T01:03:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bpx-401-bellicum-pharmaceuticals-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:53:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neo-212-neonc-technologies-metastatic-brain-tumor-likelihood-of-approval/ 2024-02-08T04:30:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-imago-biosciences-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval/ 2024-01-04T17:34:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bomedemstat-tosylate-imago-biosciences-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval/ 2024-01-04T17:34:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcar-014-bristol-myers-squibb-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-05-20T04:06:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neo-212-neonc-technologies-astrocytoma-likelihood-of-approval/ 2024-02-08T04:30:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/neo-212-neonc-technologies-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-02-08T04:30:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcar-014-bristol-myers-squibb-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-04-20T01:05:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcar-014-bristol-myers-squibb-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-04-20T01:05:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/jcar-014-bristol-myers-squibb-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-05-20T04:06:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mezagitamab-takeda-pharmaceutical-myasthenia-gravis-likelihood-of-approval/ 2024-06-19T05:52:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relacorilant-corcept-therapeutics-prostate-cancer-likelihood-of-approval/ 2025-01-21T01:03:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odronextamab-regeneron-pharmaceuticals-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:03:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/magrolimab-gilead-sciences-laryngeal-cancer-likelihood-of-approval/ 2024-06-19T05:52:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/magrolimab-gilead-sciences-oropharyngeal-cancer-likelihood-of-approval/ 2024-06-19T05:52:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/magrolimab-gilead-sciences-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-06-19T05:52:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mvxonco-1-release-therapeutics-oral-cavity-mouth-cancer-likelihood-of-approval/ 2024-03-19T00:16:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mvxonco-1-release-therapeutics-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2024-03-19T00:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/magrolimab-gilead-sciences-hypopharyngeal-cancer-likelihood-of-approval/ 2024-06-19T05:52:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mvxonco-1-release-therapeutics-chordoma-likelihood-of-approval/ 2024-01-04T17:29:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mvxonco-1-release-therapeutics-laryngeal-cancer-likelihood-of-approval/ 2024-03-19T00:16:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mvxonco-1-release-therapeutics-pharyngeal-neoplasm-likelihood-of-approval/ 2024-03-19T00:16:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctl-119-novartis-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-09-09T04:53:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctl-119-novartis-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2024-04-20T01:05:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ctl-119-novartis-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2024-09-09T04:53:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/garadacimab-csl-hereditary-angioedema-hae-c1-esterase-inhibitor-c1-inh-deficiency-likelihood-of-approval/ 2024-09-09T04:53:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegcetacoplan-apellis-pharmaceuticals-membranous-glomerulonephritis-likelihood-of-approval/ 2025-01-21T01:03:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegcetacoplan-apellis-pharmaceuticals-iga-nephropathy-berger-s-disease-likelihood-of-approval/ 2025-01-21T01:03:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talabostat-bioxcel-therapeutics-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-21T01:03:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talabostat-bioxcel-therapeutics-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:03:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talabostat-bioxcel-therapeutics-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:03:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ve-303-vedanta-biosciences-hepatic-encephalopathy-likelihood-of-approval/ 2025-01-21T01:03:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/psilocybin-ceruvia-lifesciences-cluster-headache-syndrome-cluster-headache-likelihood-of-approval/ 2025-01-21T01:03:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nimacimab-skye-bioscience-obesity-likelihood-of-approval/ 2025-01-21T01:02:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biosimilar-shanghai-henlius-biotech-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2025-01-21T01:02:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/emrusolmin-teva-pharmaceutical-industries-multiple-system-atrophy-msa-or-shy-drager-syndrome-or-multi-system-degeneration-likelihood-of-approval/ 2025-01-21T01:02:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvt-3101-f-hoffmann-la-roche-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2024-01-04T17:24:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enamptcumab-aqualung-therapeutics-acute-respiratory-distress-syndrome-likelihood-of-approval/ 2024-01-24T19:25:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivosidenib-les-laboratoires-servier-solid-tumor-likelihood-of-approval/ 2025-01-21T01:02:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obt-076-oxford-biotherapeutics-adenoid-cystic-carcinoma-acc-likelihood-of-approval/ 2024-07-05T17:45:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lorlatinib-pfizer-neuroblastoma-likelihood-of-approval/ 2024-05-20T04:05:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eflornithine-hydrochloride-panbela-therapeutics-gastric-cancer-likelihood-of-approval/ 2024-09-09T04:53:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eflornithine-hydrochloride-panbela-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-09-09T04:53:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eflornithine-hydrochloride-panbela-therapeutics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-09-09T04:53:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipn-60250-ipsen-liver-diseases-likelihood-of-approval/ 2024-05-20T04:04:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pelabresib-morphosys-chronic-idiopathic-myelofibrosis-primary-myelofibrosis-likelihood-of-approval/ 2025-01-21T01:02:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eflornithine-hydrochloride-panbela-therapeutics-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2024-01-04T17:22:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abrocitinib-pfizer-pruritus-likelihood-of-approval/ 2024-07-05T17:44:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maralixibat-chloride-mirum-pharmaceuticals-biliary-atresia-likelihood-of-approval/ 2025-01-21T01:02:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ipn-60250-ipsen-primary-biliary-cholangitis-primary-biliary-cirrhosis-likelihood-of-approval/ 2024-01-04T17:21:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amivantamab-johnson-johnson-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-21T01:02:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luaf-82422-h-lundbeck-multiple-system-atrophy-msa-or-shy-drager-syndrome-or-multi-system-degeneration-likelihood-of-approval/ 2024-06-19T05:51:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/csl-311-csl-allergic-asthma-likelihood-of-approval/ 2024-01-04T17:19:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amivantamab-johnson-johnson-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-21T01:02:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amivantamab-johnson-johnson-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-21T01:02:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lisocabtagene-maraleucel-bristol-myers-squibb-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:02:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/axicabtagene-ciloleucel-gilead-sciences-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-03-19T00:15:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efruxifermin-akero-therapeutics-metabolic-dysfunction-associated-steatotic-liver-disease-masld-likelihood-of-approval/ 2025-01-21T01:02:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chf-6333-chiesi-farmaceutici-bronchiectasis-likelihood-of-approval/ 2024-07-05T17:44:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selinexor-karyopharm-therapeutics-dedifferentiated-liposarcoma-likelihood-of-approval/ 2024-04-20T01:04:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tazarotene-gri-bio-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2025-01-21T01:02:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-00114-protagenic-therapeutics-substance-drug-abuse-likelihood-of-approval/ 2024-01-04T17:17:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-00114-protagenic-therapeutics-generalized-anxiety-disorder-gad-likelihood-of-approval/ 2025-01-21T01:02:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pt-00114-protagenic-therapeutics-treatment-resistant-depression-likelihood-of-approval/ 2025-01-21T01:02:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ni-1701-light-chain-bioscience-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-01-04T17:16:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ni-1701-light-chain-bioscience-follicular-lymphoma-likelihood-of-approval/ 2024-01-04T17:16:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ni-1701-light-chain-bioscience-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-01-04T17:16:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-21T01:01:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-21T01:01:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biosimilar-nichi-iko-pharmaceutical-lymphoma-likelihood-of-approval/ 2024-04-20T01:04:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/enfortumab-vedotin-astellas-pharma-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2025-01-21T01:01:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oteseconazole-mycovia-pharmaceuticals-cryptococcal-meningitis-likelihood-of-approval/ 2024-06-19T05:51:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/peltopepimut-s-isa-pharmaceuticals-human-papillomavirus-hpv-associated-cancer-likelihood-of-approval/ 2024-07-05T17:44:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/famitinib-jiangsu-hengrui-medicine-medullary-thyroid-cancer-likelihood-of-approval/ 2024-09-09T04:52:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/famitinib-jiangsu-hengrui-medicine-thyroid-cancer-likelihood-of-approval/ 2024-09-09T04:52:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/famitinib-jiangsu-hengrui-medicine-anaplastic-thyroid-cancer-likelihood-of-approval/ 2024-09-09T04:52:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifebemtinib-inxmed-nanjing-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-21T01:01:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nadravaleucel-gamida-cell-relapsed-multiple-myeloma-likelihood-of-approval/ 2024-01-04T17:12:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nadravaleucel-gamida-cell-refractory-multiple-myeloma-likelihood-of-approval/ 2024-01-04T17:12:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifebemtinib-inxmed-nanjing-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-06-19T05:51:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifebemtinib-inxmed-nanjing-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-21T01:01:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-137-netris-pharma-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-21T01:01:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifebemtinib-inxmed-nanjing-ovarian-cancer-likelihood-of-approval/ 2024-09-09T04:52:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ifebemtinib-inxmed-nanjing-small-cell-lung-cancer-likelihood-of-approval/ 2024-01-04T17:11:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval/ 2025-01-21T01:01:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-urethral-cancer-likelihood-of-approval/ 2025-01-21T01:01:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-137-netris-pharma-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-21T01:01:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fipaxalparant-horizon-therapeutics-idiopathic-pulmonary-fibrosis-likelihood-of-approval/ 2024-01-04T17:09:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polatuzumab-vedotin-genentech-usa-t-cell-lymphomas-likelihood-of-approval/ 2025-01-21T01:00:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polatuzumab-vedotin-genentech-usa-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-21T01:00:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-endometrial-cancer-likelihood-of-approval/ 2025-01-21T01:00:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eniluracil-processa-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2025-01-21T01:00:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fadraciclib-cyclacel-pharmaceuticals-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-21T01:00:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-21T01:00:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-f-hoffmann-la-roche-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:00:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-f-hoffmann-la-roche-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2025-01-21T01:00:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-f-hoffmann-la-roche-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-21T01:00:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/givinostat-hydrochloride-italfarmaco-duchenne-muscular-dystrophy-likelihood-of-approval/ 2024-04-20T01:03:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biogen-neuromyelitis-optica-devic-s-syndrome-likelihood-of-approval/ 2025-01-21T01:00:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rituximab-biogen-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2024-04-20T01:03:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elamipretide-hydrochloride-stealth-biotherapeutics-dry-atrophic-macular-degeneration-likelihood-of-approval/ 2024-07-05T17:43:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elamipretide-hydrochloride-stealth-biotherapeutics-geographic-atrophy-likelihood-of-approval/ 2024-07-05T17:43:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rotigotine-er-ucb-frontotemporal-dementia-ftd-likelihood-of-approval/ 2024-01-04T17:05:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-peritoneal-cancer-likelihood-of-approval/ 2025-01-20T17:10:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-21T01:00:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elamipretide-hydrochloride-stealth-biotherapeutics-friedreich-ataxia-likelihood-of-approval/ 2024-01-04T17:04:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-colon-cancer-likelihood-of-approval/ 2025-01-20T17:10:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-pancreatic-cancer-likelihood-of-approval/ 2025-01-20T17:10:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-20T17:10:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/reparixin-dompe-farmaceutici-community-acquired-pneumonia-likelihood-of-approval/ 2024-09-09T04:51:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ofatumumab-novartis-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-06-19T05:50:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ofatumumab-novartis-relapsing-multiple-sclerosis-rms-likelihood-of-approval/ 2024-06-19T05:50:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/txa-127-constant-therapeutics-ischemic-stroke-likelihood-of-approval/ 2024-09-09T04:51:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rexlemestrocel-l-mesoblast-hypoplastic-left-heart-syndrome-likelihood-of-approval/ 2025-01-20T17:09:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/masupirdine-suven-life-sciences-dementia-associated-with-alzheimer-s-disease-likelihood-of-approval/ 2025-01-20T17:10:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iti-1000-immunomic-therapeutics-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2024-01-04T17:01:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-20T17:09:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-leiomyosarcoma-likelihood-of-approval/ 2025-01-20T17:09:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisagenlecleucel-novartis-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-20T17:09:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisagenlecleucel-novartis-primary-cns-lymphoma-likelihood-of-approval/ 2025-01-20T17:09:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tisagenlecleucel-novartis-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-20T17:09:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/elinzanetant-bayer-sleep-disorders-likelihood-of-approval/ 2025-01-20T17:09:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epratuzumab-gilead-sciences-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2024-01-04T16:59:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nto-1151-ology-bioservices-neuroendocrine-tumors-likelihood-of-approval/ 2025-01-20T17:09:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-morphosys-primary-cns-lymphoma-likelihood-of-approval/ 2024-02-22T00:59:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/inebilizumab-amgen-myasthenia-gravis-likelihood-of-approval/ 2025-01-20T17:09:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/setanaxib-calliditas-therapeutics-alport-syndrome-likelihood-of-approval/ 2025-01-20T17:09:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-peritoneal-cancer-likelihood-of-approval/ 2025-01-20T17:08:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/epetraborole-an2-therapeutics-burkholderia-pseudomallei-infections-melioidosis-likelihood-of-approval/ 2025-01-20T17:08:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tafasitamab-morphosys-leukemia-likelihood-of-approval/ 2024-02-22T00:59:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cretostimogene-grenadenorepvec-cg-oncology-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2025-01-20T17:08:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-ovarian-cancer-likelihood-of-approval/ 2025-01-20T17:08:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lb-100-lixte-biotechnology-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-20T17:08:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/catequentinib-hydrochloride-advenchen-laboratories-oral-cancer-likelihood-of-approval/ 2025-01-20T17:08:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ripasudil-hydrochloride-hydrate-kowa-corneal-edema-likelihood-of-approval/ 2025-01-20T17:08:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diamyd-diamyd-medical-type-1-diabetes-juvenile-diabetes-likelihood-of-approval/ 2025-01-20T17:08:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mydicar-sardocor-congestive-heart-failure-heart-failure-likelihood-of-approval/ 2024-02-22T00:59:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/defibrotide-sodium-jazz-pharmaceuticals-sickle-cell-disease-likelihood-of-approval/ 2025-01-20T17:08:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/innate-pharma-forges-ahead-with-lacutamab-trial-post-fda-investigation/ 2024-02-01T09:19:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-ipsen-neuroendocrine-cancer-likelihood-of-approval/ 2025-01-20T17:07:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sirolimus-albumin-bound-aadi-bioscience-solid-tumor-likelihood-of-approval/ 2025-01-20T17:07:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abatacept-bristol-myers-squibb-cytopenia-likelihood-of-approval/ 2024-01-04T16:53:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mogamulizumab-kyowa-kirin-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-04-20T01:01:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mogamulizumab-kyowa-kirin-oral-cancer-likelihood-of-approval/ 2024-04-20T01:02:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2025-01-20T17:07:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dimesna-lantern-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T17:07:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pimasertib-hydrochloride-day-one-biopharmaceuticals-solid-tumor-likelihood-of-approval/ 2024-04-20T01:01:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crizotinib-pfizer-uveal-melanoma-likelihood-of-approval/ 2025-01-20T17:07:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-solid-tumor-likelihood-of-approval/ 2025-01-20T17:07:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/surufatinib-hutchison-medipharma-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-20T17:07:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xl-888-exelixis-small-intestine-cancer-likelihood-of-approval/ 2024-07-05T17:42:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xl-888-exelixis-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-07-05T17:42:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xl-888-exelixis-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2024-07-05T17:42:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xl-888-exelixis-gastric-cancer-likelihood-of-approval/ 2024-07-05T17:42:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xl-888-exelixis-hepatocellular-carcinoma-likelihood-of-approval/ 2024-07-05T17:42:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T17:07:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-04-20T01:01:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azacitidine-bristol-myers-squibb-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-20T17:07:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-t-cell-lymphomas-likelihood-of-approval/ 2025-01-20T17:07:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T17:07:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-lupus-nephritis-likelihood-of-approval/ 2024-04-20T01:01:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-systemic-mastocytosis-likelihood-of-approval/ 2024-04-20T01:01:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-20T17:07:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-pancreatic-cancer-likelihood-of-approval/ 2024-05-20T04:01:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-testicular-cancer-likelihood-of-approval/ 2024-04-20T01:01:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-04-20T01:00:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-solid-tumor-likelihood-of-approval/ 2024-04-20T01:01:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blinatumomab-amgen-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2024-04-20T01:00:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blinatumomab-amgen-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-04-20T01:00:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brentuximab-vedotin-pfizer-non-hodgkin-lymphoma-likelihood-of-approval/ 2024-04-20T01:00:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blinatumomab-amgen-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-20T17:06:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blinatumomab-amgen-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-04-20T01:00:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blinatumomab-amgen-nodal-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-04-20T01:00:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T17:06:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/selumetinib-sulfate-astrazeneca-glioma-likelihood-of-approval/ 2024-07-05T17:42:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blinatumomab-amgen-follicular-lymphoma-likelihood-of-approval/ 2024-04-20T01:00:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-polycythemia-vera-likelihood-of-approval/ 2025-01-20T17:06:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-essential-thrombocythemia-likelihood-of-approval/ 2025-01-20T17:06:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/navitoclax-dihydrochloride-abbvie-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T17:06:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2024-04-20T01:00:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ocrelizumab-f-hoffmann-la-roche-autoimmune-encephalitis-post-infectious-likelihood-of-approval/ 2024-09-09T04:50:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ocrelizumab-f-hoffmann-la-roche-relapsing-remitting-multiple-sclerosis-rrms-likelihood-of-approval/ 2024-04-20T01:00:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rt-310-resurge-therapeutics-urinary-tract-infections-likelihood-of-approval/ 2024-01-04T16:40:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/wxwh-0226-guizhou-inochini-technology-parkinson-s-disease-likelihood-of-approval/ 2024-01-04T16:40:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pf-07921186-biontech-herpes-zoster-shingles-likelihood-of-approval/ 2025-01-20T17:06:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nmez-2881529-zyus-life-sciences-neuropathic-pain-neuralgia-likelihood-of-approval/ 2024-01-04T16:39:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plx-4545-plexium-solid-tumor-likelihood-of-approval/ 2024-04-20T01:00:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/crinecerfont-neurocrine-biosciences-congenital-adrenal-hyperplasia-adrenogenital-syndrome-likelihood-of-approval/ 2024-07-05T17:42:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-cutaneous-t-cell-lymphoma-likelihood-of-approval/ 2024-09-09T04:50:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-kidney-disease-nephropathy-likelihood-of-approval/ 2024-09-09T04:50:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2024-09-09T04:50:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-metastatic-melanoma-likelihood-of-approval/ 2024-09-09T04:50:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-lupus-nephritis-likelihood-of-approval/ 2024-09-09T04:50:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avutometinib-potassium-verastem-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-20T17:06:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avutometinib-potassium-verastem-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-20T17:06:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/obinutuzumab-f-hoffmann-la-roche-systemic-lupus-erythematosus-likelihood-of-approval/ 2024-09-09T04:50:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/t-817ma-fujifilm-toyama-chemical-alzheimer-s-disease-likelihood-of-approval/ 2024-02-22T00:56:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/buntanetap-tartrate-annovis-bio-parkinson-s-disease-likelihood-of-approval/ 2025-01-20T17:06:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/briquilimab-jasper-therapeutics-chronic-urticaria-or-hives-likelihood-of-approval/ 2024-03-19T00:11:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nmra-m4r-neumora-therapeutics-net-present-value/ 2024-01-04T16:27:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/janx-007-janux-therapeutics-net-present-value/ 2024-06-13T18:54:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tyra-200-tyra-biosciences-net-present-value/ 2024-06-13T18:55:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maridebart-cafraglutide-amgen-net-present-value/ 2024-04-16T17:04:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cmg-901-keymed-biosciences-net-present-value/ 2024-12-13T02:50:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986288-bristol-myers-squibb-net-present-value/ 2024-04-16T17:04:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-net-present-value/ 2024-12-13T02:50:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nn-7769-novo-nordisk-net-present-value/ 2024-01-04T16:25:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/autogene-cevumeran-f-hoffmann-la-roche-net-present-value/ 2024-07-02T02:11:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/golcadomide-bristol-myers-squibb-net-present-value/ 2024-04-16T17:04:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutikizumab-abbvie-net-present-value/ 2024-04-16T17:04:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nemvaleukin-alfa-alkermes-net-present-value/ 2024-01-05T08:03:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/livmoniplimab-abbvie-net-present-value/ 2024-07-02T02:11:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/cvs-to-remove-humira-from-reimbursement-lists-in-biosimilar-push/ 2024-01-04T15:06:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tango-therapeutics-doses-first-patient-with-usp1-inhibitor-trial/ 2024-01-04T16:52:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/esperion-daiichi-sankyo-europe-partnership/ 2024-01-04T10:51:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/agioss-mitapivat-meets-endpoints-in-phase-iii-thalassemia-trial/ 2024-01-04T14:37:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bridgene-galapagos-oncology-drugs/ 2024-01-04T10:45:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pfizer-approval-haemophilia-b-therapy/ 2024-01-04T09:14:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/enyo-39m-funding-vonafexor/ 2024-01-04T09:13:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/inside-the-world-of-priority-review-vouchers-where-time-is-money-part-i/ 2024-01-12T00:06:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/boehringer-reinforces-interest-in-nash-with-new-2bn-deal/ 2024-01-03T17:36:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/novartis-allies-with-voyager-to-develop-gene-therapies-in-1-3bn-deal/ 2024-01-03T16:40:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/signal-ftc-granted-injunction-to-pause-iqvias-acquisition-of-propel-media/ 2024-01-03T16:43:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/sponsored/expert-analysis-the-latest-in-hiv-research-and-clinical-trials/ 2024-03-18T16:49:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/diakonos-brain-tumour-vaccine-wins-fdas-orphan-drug-designation/ 2024-01-03T12:49:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/mhra-procedure-medicine-approvals/ 2024-01-03T10:55:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/oragenics-acquires-neurological-assets/ 2024-01-03T10:49:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/ema-bms-repotrectinib-application/ 2024-01-03T09:08:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/medilink-roche-cancer-drug/ 2024-01-03T09:12:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/immunitybio-inks-320m-deal-to-advance-bladder-cancer-drug-and-boost-pipeline/ 2024-01-02T18:40:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/amd-market-forecast-2031/ 2024-01-02T14:06:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/analyst-comment/gout-market-growth-ults-2022-2032/ 2024-01-02T13:35:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/apollo-funds-pipeline-programmes/ 2024-01-02T12:30:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/china-astrazeneca-sanofi-rsv-antibody/ 2024-01-02T12:21:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/valneva-adjusts-2023-financial-guidance-after-priority-voucher-sale-delay/ 2024-01-02T11:03:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tiumbio-raises-12m-to-advance-clinical-development/ 2024-01-03T11:11:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/tmc-idrs-therapy-leukaemia/ 2024-01-02T09:48:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/pyc-google-cloud-medicines/ 2024-01-02T09:50:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/magazine-pharmas-path-to-net-zero-targeting-scope-3-emissions/ 2023-12-18T15:54:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/fda-warns-of-rare-hypersensitivity-reaction-due-to-antiseizure-drugs/ 2023-12-29T11:47:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/enveric-mental-health-disorders/ 2023-12-29T09:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-bags-uk-advanced-melanoma-win-for-opdualag/ 2024-01-02T12:14:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/jj-jumps-on-adc-train-signs-1-7bn-licensing-deal-with-legochem/ 2023-12-28T11:09:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/elpiscience-astellas-macrophage-engagers/ 2023-12-28T10:26:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/artbio-divulges-plans-for-proprietary-isotope-manufacturing-technology/ 2023-12-27T11:55:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/astrazeneca-buys-chinese-car-t-biotech-gracell-in-a-1-2bn-deal/ 2024-01-17T09:54:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bristol-myers-squibb-to-acquire-rayzebio/ 2023-12-27T13:25:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/features/difficult-biotech-investment-ecosystem-forces-focus-on-value/ 2024-01-08T11:21:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/odm-212-orion-solid-tumor-likelihood-of-approval/ 2024-04-20T00:44:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kb-707-krystal-biotech-solid-tumor-likelihood-of-approval/ 2025-01-20T16:51:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:51:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrx-0706-adcentrx-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:50:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9550-astrazeneca-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-20T16:50:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ft-522-fate-therapeutics-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-20T16:50:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ft-522-fate-therapeutics-follicular-lymphoma-likelihood-of-approval/ 2025-01-20T16:50:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ft-522-fate-therapeutics-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-20T16:50:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-04-20T00:44:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-036c-minghui-pharmaceutical-shanghai-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-09-09T04:41:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9592-astrazeneca-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:50:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-9592-astrazeneca-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-20T16:50:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/caba-201-cabaletta-bio-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-20T16:50:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pyx-201-pyxis-oncology-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-05T17:27:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/janx-008-janux-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:50:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hcw-9218-hcw-biologics-rectal-cancer-likelihood-of-approval/ 2025-01-20T16:49:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hcw-9218-hcw-biologics-liver-cancer-likelihood-of-approval/ 2025-01-20T16:49:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/diakine-dk210-egfr-deka-biosciences-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:49:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vx-103-vaxess-technologies-seasonal-influenza-likelihood-of-approval/ 2023-12-26T21:13:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:49:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-ocular-melanoma-likelihood-of-approval/ 2025-01-20T16:49:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-duodenal-cancer-likelihood-of-approval/ 2025-01-20T16:49:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-20T16:49:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-thymoma-thymic-epithelial-tumor-likelihood-of-approval/ 2025-01-20T16:49:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-kidney-cancer-renal-cell-cancer-likelihood-of-approval/ 2025-01-20T16:49:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-cervical-cancer-likelihood-of-approval/ 2025-01-20T16:49:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/agent-797-mink-therapeutics-colorectal-cancer-likelihood-of-approval/ 2025-01-20T16:48:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:48:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lbl-007-beigene-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-20T16:48:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/grwd-5769-grey-wolf-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:48:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polzastobart-concentra-biosciences-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2024-07-05T17:24:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polzastobart-concentra-biosciences-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-07-05T17:24:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ozuriftamab-vedotin-bioatla-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:48:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kt-474-kymera-therapeutics-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2025-01-20T16:48:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ph-762-phio-pharmaceuticals-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:47:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sor-007-nanology-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T16:47:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/casdozokitug-coherus-biosciences-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:47:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/casdozokitug-coherus-biosciences-solid-tumor-likelihood-of-approval/ 2025-01-20T16:47:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/casdozokitug-coherus-biosciences-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-20T16:47:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chs-114-coherus-biosciences-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:47:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/chs-114-coherus-biosciences-solid-tumor-likelihood-of-approval/ 2025-01-20T16:47:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:47:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oleclumab-astrazeneca-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-20T16:46:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oleclumab-astrazeneca-prostate-cancer-likelihood-of-approval/ 2025-01-20T16:46:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2025-01-20T16:46:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:46:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/envafolimab-alphamab-oncology-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2025-01-20T16:46:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nedisertib-merck-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:46:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cisplatin-vinblastine-sulphate-intensity-therapeutics-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2025-01-20T16:46:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donafenib-tosylate-suzhou-zelgen-biopharmaceutical-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2024-09-09T04:36:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-20T16:45:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemvidutide-altimmune-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-20T16:45:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2025-01-20T16:45:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-non-muscle-invasive-bladder-cancer-nmibc-superficial-bladder-cancer-likelihood-of-approval/ 2025-01-20T16:45:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efruxifermin-akero-therapeutics-metabolic-dysfunction-associated-steatohepatitis-mash-likelihood-of-approval/ 2025-01-20T16:45:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-20T16:45:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:45:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-20T16:45:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:44:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-20T16:44:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-20T16:44:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-endometrial-cancer-likelihood-of-approval/ 2025-01-20T16:44:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-solid-tumor-likelihood-of-approval/ 2025-01-20T16:44:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-gastric-cancer-likelihood-of-approval/ 2025-01-20T16:44:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-lymphoma-likelihood-of-approval/ 2025-01-20T16:44:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-cervical-cancer-likelihood-of-approval/ 2025-01-20T16:44:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lifileucel-iovance-biotherapeutics-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:44:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-cutaneous-squamous-cell-carcinoma-cscc-likelihood-of-approval/ 2025-01-20T16:44:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-20T16:44:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-head-and-neck-squamous-cell-carcinoma-hnsc-likelihood-of-approval/ 2025-01-20T16:44:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/setanaxib-calliditas-therapeutics-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:43:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-recurrent-head-and-neck-squamous-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:43:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fruquintinib-takeda-pharmaceutical-rectal-cancer-likelihood-of-approval/ 2025-01-20T16:43:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fruquintinib-takeda-pharmaceutical-endometrial-cancer-likelihood-of-approval/ 2025-01-20T16:43:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fruquintinib-takeda-pharmaceutical-solid-tumor-likelihood-of-approval/ 2025-01-20T16:43:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-malignant-mesothelioma-likelihood-of-approval/ 2025-01-20T16:43:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lpxti-641-lapix-therapeutics-multiple-sclerosis-likelihood-of-approval/ 2025-01-20T16:43:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vls-1488-volastra-therapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-20T16:42:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blm-02d1-systimmune-gastrointestinal-tumor-likelihood-of-approval/ 2024-05-20T03:40:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvcov-2-nanoviricides-middle-east-respiratory-syndrome-mers-likelihood-of-approval/ 2024-09-09T04:33:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nvcov-2-nanoviricides-respiratory-syncytial-virus-rsv-infections-likelihood-of-approval/ 2024-09-09T04:33:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncarlytics-imugene-ovarian-cancer-likelihood-of-approval/ 2025-01-20T16:25:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-20T16:25:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-20T16:25:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-20T16:25:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-20T16:25:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-endometrial-cancer-likelihood-of-approval/ 2025-01-20T16:25:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T16:25:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sacituzumab-tirumotecan-merck-gastric-cancer-likelihood-of-approval/ 2025-01-20T16:25:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-synovial-sarcoma-likelihood-of-approval/ 2025-01-20T16:24:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-20T16:24:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-20T16:24:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-coherus-biosciences-solid-tumor-likelihood-of-approval/ 2025-01-20T16:24:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-20T16:24:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-gastric-cancer-likelihood-of-approval/ 2025-01-20T16:24:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-coherus-biosciences-melanoma-likelihood-of-approval/ 2025-01-20T16:24:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ima-203-immatics-uveal-melanoma-likelihood-of-approval/ 2024-07-05T06:37:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-endometrial-cancer-likelihood-of-approval/ 2025-01-20T16:23:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-metastatic-melanoma-likelihood-of-approval/ 2025-01-20T16:23:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mbrc-101-mbrace-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-04-19T17:41:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mbrc-101-mbrace-therapeutics-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2024-04-19T17:41:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mbrc-101-mbrace-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-19T17:41:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mbrc-101-mbrace-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-19T17:41:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nb-001-nobias-therapeutics-digeorge-syndrome-likelihood-of-approval/ 2025-01-20T16:23:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blm-02d1-systimmune-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-05-20T03:36:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oncarlytics-imugene-solid-tumor-likelihood-of-approval/ 2025-01-20T16:22:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omn-6-omnix-medical-hospital-acquired-pneumonia-hap-likelihood-of-approval/ 2025-01-20T16:22:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-20T16:22:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:22:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-hematological-tumor-likelihood-of-approval/ 2025-01-20T16:22:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-metastatic-melanoma-likelihood-of-approval/ 2025-01-20T16:22:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-20T16:21:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-20T16:21:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-head-and-neck-cancer-likelihood-of-approval/ 2025-01-20T16:21:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabometyx-exelixis-ovarian-cancer-likelihood-of-approval/ 2025-01-20T16:21:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polzastobart-concentra-biosciences-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2024-07-05T18:20:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polzastobart-concentra-biosciences-solid-tumor-likelihood-of-approval/ 2024-07-05T06:33:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/polzastobart-concentra-biosciences-ovarian-cancer-likelihood-of-approval/ 2024-07-05T06:33:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/revumenib-citrate-syndax-pharmaceuticals-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-20T16:21:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/io-202-immune-onc-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-19T17:36:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-080-first-condor-group-esophageal-cancer-likelihood-of-approval/ 2024-07-05T06:29:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-080-first-condor-group-gastric-cancer-likelihood-of-approval/ 2024-07-05T06:29:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ct-080-first-condor-group-colorectal-cancer-likelihood-of-approval/ 2024-07-05T06:29:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/gnc-035-systimmune-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-20T16:18:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-09-09T04:23:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snk-02-nkgen-biotech-solid-tumor-likelihood-of-approval/ 2024-09-09T04:18:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-5863-astrazeneca-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:15:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vrn-07-oric-pharmaceuticals-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-20T02:16:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vrn-07-oric-pharmaceuticals-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T02:16:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denfivontinib-genosco-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T02:15:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/denfivontinib-genosco-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T02:14:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-botidotin-klus-pharma-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T02:11:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-post-transplant-lymphoproliferative-disorder-likelihood-of-approval/ 2025-01-20T02:11:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-splenic-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-20T02:11:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-extranodal-marginal-zone-b-cell-lymphoma-mucosa-associated-lymphoid-tissue-or-malt-lymphoma-likelihood-of-approval/ 2025-01-20T02:11:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nibrozetone-epicentrx-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T02:10:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alxn-1920-alexion-pharmaceuticals-kidney-disease-nephropathy-likelihood-of-approval/ 2023-12-26T18:12:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-5335-astrazeneca-solid-tumor-likelihood-of-approval/ 2025-01-19T18:27:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/azd-5335-astrazeneca-ovarian-cancer-likelihood-of-approval/ 2025-01-19T18:27:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hrs-8427-jiangsu-hengrui-medicine-urinary-tract-infections-likelihood-of-approval/ 2025-01-19T18:27:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/am-928-academab-biomedical-solid-tumor-likelihood-of-approval/ 2024-04-19T17:02:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/infliximab-biosimilar-xentria-pulmonary-sarcoidosis-likelihood-of-approval/ 2025-01-19T18:27:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tnx-1900-tonix-pharmaceuticals-holding-social-anxiety-disorder-sad-social-phobia-likelihood-of-approval/ 2024-06-14T03:57:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanubrutinib-beigene-refractory-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:22:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanubrutinib-beigene-relapsed-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:22:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zenocutuzumab-merus-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T18:22:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thymalfasin-sciclone-pharmaceuticals-thymic-carcinoma-likelihood-of-approval/ 2025-01-19T18:21:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/thymalfasin-sciclone-pharmaceuticals-thymoma-thymic-epithelial-tumor-likelihood-of-approval/ 2025-01-19T18:21:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/clofazimine-mannkind-mycobacterium-infections-likelihood-of-approval/ 2025-01-19T18:20:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cc-95775-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-09-09T02:17:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986449-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2025-01-19T18:19:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sar-441566-sanofi-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-19T18:18:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iov-1042-iconovir-bio-solid-tumor-likelihood-of-approval/ 2024-04-19T16:42:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T18:16:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:16:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:16:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:16:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-pleomorphic-liposarcoma-likelihood-of-approval/ 2025-01-19T18:11:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-angiosarcoma-likelihood-of-approval/ 2025-01-19T18:11:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-chondrosarcoma-likelihood-of-approval/ 2025-01-19T18:10:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tlx-250-telix-pharmaceuticals-solid-tumor-likelihood-of-approval/ 2025-01-19T18:10:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/guselkumab-johnson-johnson-crohn-s-disease-regional-enteritis-likelihood-of-approval/ 2025-01-19T18:10:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-kaposi-sarcoma-likelihood-of-approval/ 2025-01-19T18:10:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-esophageal-cancer-likelihood-of-approval/ 2025-01-19T18:10:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:10:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/kyv-101-kyverna-therapeutics-lupus-nephritis-likelihood-of-approval/ 2025-01-19T18:10:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T18:08:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-19T18:08:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/eribulin-mesylate-eisai-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-09-09T02:04:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sail-66-chugai-pharmaceutical-solid-tumor-likelihood-of-approval/ 2025-01-19T18:07:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-706-abbvie-neuroendocrine-carcinoma-likelihood-of-approval/ 2025-01-19T18:07:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-706-abbvie-oligodendroglioma-likelihood-of-approval/ 2025-01-19T18:07:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/asp-3082-astellas-pharma-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T18:06:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-squamous-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:06:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986406-bristol-myers-squibb-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T18:06:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zl-1218-zai-lab-solid-tumor-likelihood-of-approval/ 2024-09-09T02:04:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amg-193-amgen-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-19T18:06:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivx-037-immvirx-metastatic-ovarian-cancer-likelihood-of-approval/ 2025-01-19T18:05:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivx-037-immvirx-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-19T18:05:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivx-037-immvirx-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-19T18:05:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivx-037-immvirx-solid-tumor-likelihood-of-approval/ 2025-01-19T18:05:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivx-037-immvirx-gastric-cancer-likelihood-of-approval/ 2025-01-19T18:05:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sns-101-sensei-biotherapeutics-solid-tumor-likelihood-of-approval/ 2024-07-05T05:44:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/a-2b530-a2-biotherapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-06-14T01:57:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-15025-beigene-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:03:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-15025-beigene-gastric-cancer-likelihood-of-approval/ 2025-01-19T18:02:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1701-bliss-biopharmaceutical-hangzhou-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-19T18:02:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1701-bliss-biopharmaceutical-hangzhou-bladder-cancer-likelihood-of-approval/ 2025-01-19T18:02:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bb-1701-bliss-biopharmaceutical-hangzhou-colon-cancer-likelihood-of-approval/ 2025-01-19T18:02:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zb-131-zielbio-extrahepatic-bile-duct-cancer-likelihood-of-approval/ 2024-07-05T05:20:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zb-131-zielbio-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-07-05T05:20:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ociperlimab-beigene-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2024-09-09T02:02:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-19T18:01:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T18:01:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-solid-tumor-likelihood-of-approval/ 2025-01-19T18:01:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-19T18:01:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabometyx-exelixis-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval/ 2025-01-19T17:51:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/news/bms-to-acquire-karuna/ 2023-12-27T13:25:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sbp-0069330-camino-pharma-smoking-cessation-likelihood-of-approval/ 2023-12-26T06:23:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mufemilast-tianjin-hemay-pharmaceutical-atopic-dermatitis-atopic-eczema-likelihood-of-approval/ 2024-05-20T02:12:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ub-312-vaxxinity-parkinson-s-disease-likelihood-of-approval/ 2025-01-19T17:46:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-colon-carcinoma-likelihood-of-approval/ 2025-01-19T17:45:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-anal-cancer-likelihood-of-approval/ 2025-01-19T17:45:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-cervical-cancer-likelihood-of-approval/ 2025-01-19T17:45:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ve-303-vedanta-biosciences-clostridioides-difficile-infections-clostridium-difficile-associated-disease-likelihood-of-approval/ 2025-01-19T17:44:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/debio-0123-debiopharm-international-astrocytoma-likelihood-of-approval/ 2025-01-19T17:44:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivosidenib-les-laboratoires-servier-low-grade-glioma-likelihood-of-approval/ 2025-01-19T17:44:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivosidenib-les-laboratoires-servier-chondrosarcoma-likelihood-of-approval/ 2025-01-19T17:43:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-antibody-mediated-rejection-amr-likelihood-of-approval/ 2025-01-19T17:43:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/avelumab-merck-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T17:43:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imifoplatin-promontory-therapeutics-thymoma-thymic-epithelial-tumor-likelihood-of-approval/ 2025-01-19T17:43:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imifoplatin-promontory-therapeutics-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T17:43:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imifoplatin-promontory-therapeutics-ovarian-cancer-likelihood-of-approval/ 2025-01-19T17:42:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-lung-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:42:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lanadelumab-takeda-pharmaceutical-angioedema-likelihood-of-approval/ 2025-01-19T17:41:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lutikizumab-abbvie-hidradenitis-suppurativa-likelihood-of-approval/ 2025-01-19T17:41:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-ureter-cancer-likelihood-of-approval/ 2025-01-19T17:41:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-anal-cancer-likelihood-of-approval/ 2025-01-19T17:41:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nadunolimab-cantargia-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-19T17:41:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brolucizumab-novartis-polypoidal-choroidal-vasculopathy-likelihood-of-approval/ 2025-01-19T17:26:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-carcinoma-of-unknown-primary-occult-primary-tumor-cancer-of-unknown-primary-likelihood-of-approval/ 2025-01-19T17:26:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-19T17:26:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-gliosarcoma-likelihood-of-approval/ 2025-01-19T17:26:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-uterine-cancer-likelihood-of-approval/ 2025-01-19T17:25:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-adrenocortical-carcinoma-adrenal-cortex-cancer-likelihood-of-approval/ 2025-01-19T17:25:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-19T17:25:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-gastritis-likelihood-of-approval/ 2025-01-19T17:25:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-gastroenteritis-likelihood-of-approval/ 2025-01-19T17:25:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-bullous-pemphigoid-likelihood-of-approval/ 2025-01-19T17:25:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dupilumab-regeneron-pharmaceuticals-systemic-sclerosis-scleroderma-likelihood-of-approval/ 2025-01-19T17:25:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-19T17:25:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-metastatic-breast-cancer-likelihood-of-approval/ 2025-01-19T17:25:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abemaciclib-eli-lilly-and-co-breast-cancer-likelihood-of-approval/ 2025-01-19T17:24:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-pediatric-diffuse-intrinsic-pontine-glioma-likelihood-of-approval/ 2025-01-19T17:24:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-high-grade-glioma-likelihood-of-approval/ 2025-01-19T17:24:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tnx-1900-tonix-pharmaceuticals-holding-obesity-likelihood-of-approval/ 2024-06-14T01:44:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tipiracil-hydrochloride-trifluridine-taiho-oncology-rectal-cancer-likelihood-of-approval/ 2025-01-19T17:23:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sparsentan-travere-therapeutics-focal-segmental-glomerulosclerosis-fsgs-likelihood-of-approval/ 2025-01-19T17:23:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-penile-cancer-likelihood-of-approval/ 2025-01-19T17:23:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/carfilzomib-amgen-multiple-myeloma-kahler-disease-likelihood-of-approval/ 2025-01-19T17:23:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tocilizumab-f-hoffmann-la-roche-diffuse-large-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T17:22:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fruquintinib-takeda-pharmaceutical-angiosarcoma-likelihood-of-approval/ 2025-01-19T17:22:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fruquintinib-takeda-pharmaceutical-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T17:22:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-esophageal-cancer-likelihood-of-approval/ 2025-01-19T17:22:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T17:22:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-colorectal-cancer-likelihood-of-approval/ 2025-01-19T17:22:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-lung-cancer-likelihood-of-approval/ 2025-01-19T17:22:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cbp-1019-coherent-biopharma-breast-cancer-likelihood-of-approval/ 2025-01-19T17:21:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baricitinib-eli-lilly-and-co-polymyalgia-rheumatica-pmr-likelihood-of-approval/ 2025-01-19T17:21:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-osteosarcoma-likelihood-of-approval/ 2025-01-19T17:21:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-hodgkin-lymphoma-b-cell-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-19T17:21:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-t-cell-leukemia-likelihood-of-approval/ 2025-01-19T17:20:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-primary-systemic-amyloidosis-likelihood-of-approval/ 2025-01-19T17:20:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-lymphoma-likelihood-of-approval/ 2025-01-19T17:20:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-19T17:20:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-19T17:20:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/anvatabart-opadotin-ambrx-biopharma-solid-tumor-likelihood-of-approval/ 2024-07-05T01:51:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ubidecarenone-bpgbio-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-19T17:20:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-natural-killer-cell-lymphomas-likelihood-of-approval/ 2025-01-19T17:19:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-19T17:19:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-esophageal-cancer-likelihood-of-approval/ 2025-01-19T17:19:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/regorafenib-bayer-gastric-cancer-likelihood-of-approval/ 2025-01-19T17:19:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-precursor-b-cell-lymphoblastic-leukemia-lymphoma-likelihood-of-approval/ 2025-01-19T17:19:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-high-grade-glioma-likelihood-of-approval/ 2025-01-19T17:19:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-rhabdomyosarcoma-likelihood-of-approval/ 2025-01-19T17:18:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T17:18:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-ewing-sarcoma-likelihood-of-approval/ 2025-01-19T17:18:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-metastatic-melanoma-likelihood-of-approval/ 2025-01-19T17:18:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-colorectal-cancer-likelihood-of-approval/ 2025-01-19T17:18:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acp-204-acadia-pharmaceuticals-alzheimer-s-disease-likelihood-of-approval/ 2024-07-05T01:49:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-gastric-cancer-likelihood-of-approval/ 2025-01-19T17:18:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pralsetinib-blueprint-medicines-solid-tumor-likelihood-of-approval/ 2024-04-19T01:04:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T17:17:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T17:17:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stenoparib-allarity-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T17:17:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-myeloproliferative-disorders-likelihood-of-approval/ 2025-01-19T17:17:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-solid-tumor-likelihood-of-approval/ 2025-01-19T17:17:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-19T17:17:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-15025-beigene-solid-tumor-likelihood-of-approval/ 2025-01-19T17:17:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-colorectal-cancer-likelihood-of-approval/ 2025-01-19T17:16:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-peritoneal-cancer-likelihood-of-approval/ 2025-01-19T17:16:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-amyloidosis-likelihood-of-approval/ 2025-01-19T17:16:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-706-abbvie-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-19T17:01:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/acp-204-acadia-pharmaceuticals-psychosis-likelihood-of-approval/ 2024-07-05T01:47:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ulefnersen-sodium-ionis-pharmaceuticals-amyotrophic-lateral-sclerosis-likelihood-of-approval/ 2023-12-26T02:30:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-solid-tumor-likelihood-of-approval/ 2025-01-19T17:01:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T17:01:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/blm-02d1-systimmune-solid-tumor-likelihood-of-approval/ 2024-05-20T01:50:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T17:00:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-706-abbvie-neuroendocrine-gastroenteropancreatic-tumors-gep-net-likelihood-of-approval/ 2025-01-19T17:00:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-706-abbvie-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T17:00:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ucb-0022-ucb-parkinson-s-disease-likelihood-of-approval/ 2025-01-19T17:00:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-19T17:00:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-metastatic-pancreatic-cancer-likelihood-of-approval/ 2025-01-21T16:52:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hcw-9218-hcw-biologics-solid-tumor-likelihood-of-approval/ 2025-01-19T17:00:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ono-2020-ono-pharmaceutical-neurodegenerative-diseases-likelihood-of-approval/ 2024-01-08T18:30:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yh-001-eucure-beijing-biopharma-solid-tumor-likelihood-of-approval/ 2025-01-21T16:51:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-1084-merck-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:59:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maat-033-maat-pharma-chemotherapy-effects-likelihood-of-approval/ 2025-01-19T16:59:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-521-arcus-biosciences-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-19T16:58:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ab-521-arcus-biosciences-solid-tumor-likelihood-of-approval/ 2025-01-19T16:58:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/xrd-0394-xrad-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T16:58:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/abbv-706-abbvie-solid-tumor-likelihood-of-approval/ 2025-01-19T16:58:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mk-8527-merck-human-immunodeficiency-virus-hiv-infections-aids-likelihood-of-approval/ 2024-04-19T00:54:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-leptomeningeal-disease-neoplastic-meningitis-leptomeningeal-carcinomatosis-likelihood-of-approval/ 2024-07-05T01:45:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/omn-6-omnix-medical-ventilator-associated-pneumonia-vap-likelihood-of-approval/ 2025-01-19T16:57:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-colorectal-cancer-likelihood-of-approval/ 2025-01-19T16:57:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:57:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/hcw-9218-hcw-biologics-ovarian-cancer-likelihood-of-approval/ 2025-01-19T16:57:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/stc-15-storm-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T16:56:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yh-001-eucure-beijing-biopharma-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-21T16:51:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ttx-030-trishula-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T16:56:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brexucabtagene-autoleucel-gilead-sciences-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T16:56:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sunobinop-tosylate-imbrium-therapeutics-insomnia-likelihood-of-approval/ 2025-01-19T16:56:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zb-131-zielbio-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-07-05T01:43:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgc-0228-brightgene-bio-medical-technology-esophageal-cancer-likelihood-of-approval/ 2025-01-19T16:55:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zb-131-zielbio-metastatic-pancreatic-cancer-likelihood-of-approval/ 2024-07-05T01:43:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ava-6000-avacta-life-sciences-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-19T16:55:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-chronic-lymphocytic-leukemia-cll-likelihood-of-approval/ 2025-01-19T16:55:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-genexine-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-19T16:55:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pemigatinib-incyte-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T01:42:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-19T16:54:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tunlametinib-binjiang-pharma-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-19T16:54:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-epithelial-ovarian-cancer-likelihood-of-approval/ 2025-01-19T16:53:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-19T16:53:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/telisotuzumab-vedotin-abbvie-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:53:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-myelofibrosis-likelihood-of-approval/ 2024-09-09T01:45:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-19T16:53:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-burkitt-lymphoma-likelihood-of-approval/ 2025-01-19T16:53:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-post-essential-thrombocythemia-myelofibrosis-post-et-mf-likelihood-of-approval/ 2024-09-09T01:44:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vudalimab-xencor-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:52:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-solid-tumor-likelihood-of-approval/ 2025-01-19T16:52:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T16:52:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/loncastuximab-tesirine-swedish-orphan-biovitrum-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-19T16:52:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-19T16:52:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/exagamglogene-autotemcel-crispr-therapeutics-sickle-cell-disease-likelihood-of-approval/ 2025-01-19T16:51:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-post-polycythemia-vera-myelofibrosis-ppv-mf-likelihood-of-approval/ 2024-09-09T01:43:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitoxantrone-hydrochloride-cspc-pharmaceutical-group-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T16:51:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-986178-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-09-09T01:43:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/yson-001-yisheng-biopharma-solid-tumor-likelihood-of-approval/ 2024-04-19T00:28:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-solid-tumor-likelihood-of-approval/ 2025-01-19T16:51:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/berzosertib-merck-solid-tumor-likelihood-of-approval/ 2024-07-05T01:29:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-19T16:45:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vobramitamab-duocarmazine-macrogenics-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2025-01-19T16:45:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-19T16:44:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-19T16:44:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-19T16:44:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-19T16:44:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mitapivat-sulfate-agios-pharmaceuticals-beta-thalassaemia-likelihood-of-approval/ 2024-05-20T01:36:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/donafenib-tosylate-suzhou-zelgen-biopharmaceutical-solid-tumor-likelihood-of-approval/ 2024-09-09T01:41:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/plogosertib-cyclacel-pharmaceuticals-leukemia-likelihood-of-approval/ 2025-01-19T16:44:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-dermatomyositis-likelihood-of-approval/ 2025-01-19T16:43:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bemarituzumab-amgen-fallopian-tube-cancer-likelihood-of-approval/ 2025-01-19T16:43:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/alectinib-f-hoffmann-la-roche-solid-tumor-likelihood-of-approval/ 2025-01-19T16:43:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-likelihood-of-approval/ 2025-01-19T16:43:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ribociclib-succinate-novartis-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-19T16:43:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pac-1-vanquish-oncology-solid-tumor-likelihood-of-approval/ 2025-01-19T16:43:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-ovarian-cancer-likelihood-of-approval/ 2025-01-19T16:43:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rvu-120-ryvu-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-19T16:43:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-kaposi-sarcoma-likelihood-of-approval/ 2025-01-19T16:42:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-chronic-inflammatory-demyelinating-polyneuropathy-cidp-likelihood-of-approval/ 2025-01-19T16:42:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-bladder-cancer-likelihood-of-approval/ 2025-01-19T16:42:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-19T16:42:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-marginal-zone-b-cell-lymphoma-likelihood-of-approval/ 2025-01-19T16:42:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-b-cell-non-hodgkin-lymphoma-likelihood-of-approval/ 2025-01-19T16:42:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-19T16:42:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-19T16:42:18+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-prostate-cancer-likelihood-of-approval/ 2025-01-19T16:42:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-gastric-cancer-likelihood-of-approval/ 2025-01-19T16:42:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bms-813160-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2025-01-19T16:41:57+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-basal-cell-carcinoma-basal-cell-epithelioma-likelihood-of-approval/ 2025-01-19T16:41:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-peripheral-t-cell-lymphomas-ptcl-likelihood-of-approval/ 2025-01-19T16:41:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/np-137-netris-pharma-hepatocellular-carcinoma-likelihood-of-approval/ 2025-01-19T16:41:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-skin-cancer-likelihood-of-approval/ 2025-01-19T16:41:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/venetoclax-abbvie-b-cell-acute-lymphocytic-leukemia-b-cell-acute-lymphoblastic-leukaemia-likelihood-of-approval/ 2025-01-19T16:41:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-19T16:41:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-19T16:41:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-19T16:40:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-19T16:40:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/erdafitinib-johnson-johnson-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:40:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T16:40:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/dabrafenib-mesylate-novartis-hairy-cell-leukemia-likelihood-of-approval/ 2025-01-19T16:40:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T16:40:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/olaparib-astrazeneca-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-19T16:39:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-19T16:39:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-acute-lymphocytic-leukemia-all-acute-lymphoblastic-leukemia-likelihood-of-approval/ 2025-01-19T16:39:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/daratumumab-johnson-johnson-lymphoblastic-lymphoma-likelihood-of-approval/ 2025-01-19T16:39:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-head-and-neck-cancer-likelihood-of-approval/ 2024-07-05T06:18:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rhenium-186re-obisbemeda-plus-therapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-07-05T06:18:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-20T02:16:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvilostomig-systimmune-gastric-cancer-likelihood-of-approval/ 2025-01-20T02:16:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-gliosarcoma-likelihood-of-approval/ 2025-01-20T02:14:31+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-20T02:14:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2025-01-20T02:14:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/puxitatug-samrotecan-astrazeneca-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2024-09-09T03:30:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-20T02:10:51+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tocilizumab-chugai-pharmaceutical-follicular-lymphoma-likelihood-of-approval/ 2025-01-20T02:10:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amivantamab-johnson-johnson-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-19T18:26:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-metastatic-liver-cancer-likelihood-of-approval/ 2025-01-19T18:25:34+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-refractory-multiple-myeloma-likelihood-of-approval/ 2025-01-19T18:24:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-waldenstrom-macroglobulinemia-lymphoplasmacytic-lymphoma-likelihood-of-approval/ 2025-01-19T18:24:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-relapsed-multiple-myeloma-likelihood-of-approval/ 2025-01-19T18:24:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-mantle-cell-lymphoma-likelihood-of-approval/ 2025-01-19T18:24:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sonrotoclax-beigene-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:23:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-oral-cavity-mouth-cancer-likelihood-of-approval/ 2025-01-19T18:23:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-laryngeal-cancer-likelihood-of-approval/ 2025-01-19T18:23:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-19T18:23:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zanzalintinib-fumarate-exelixis-hypopharyngeal-cancer-likelihood-of-approval/ 2025-01-19T18:23:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/iruplinalkib-qilu-pharmaceutical-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:22:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lp-184-lantern-pharma-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T18:22:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-primary-sjogren-s-syndrome-likelihood-of-approval/ 2025-01-19T18:22:11+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nogapendekin-alfa-immunitybio-hereditary-nonpolyposis-colon-cancer-likelihood-of-approval/ 2025-01-19T18:21:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nivolumab-bristol-myers-squibb-meningioma-likelihood-of-approval/ 2025-01-19T18:19:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-esophageal-cancer-likelihood-of-approval/ 2025-01-19T18:18:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-adenocarcinoma-of-the-gastroesophageal-junction-likelihood-of-approval/ 2025-01-19T18:18:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T18:18:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-gastric-cancer-likelihood-of-approval/ 2025-01-19T18:18:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-ovarian-cancer-likelihood-of-approval/ 2025-01-19T18:18:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lm-302-bristol-myers-squibb-colorectal-cancer-likelihood-of-approval/ 2025-01-19T18:18:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sy-5609-syros-pharmaceuticals-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T18:15:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-coherus-biosciences-chondrosarcoma-likelihood-of-approval/ 2025-01-19T18:15:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-coherus-biosciences-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-19T18:15:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-metastatic-renal-cell-carcinoma-likelihood-of-approval/ 2025-01-19T18:14:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tiragolumab-genentech-usa-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2025-01-19T18:14:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/afm-24i-affimed-lung-cancer-likelihood-of-approval/ 2025-01-19T18:14:40+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efineptakin-alfa-neoimmunetech-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-19T18:14:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ivarmacitinib-sulfate-jiangsu-hengrui-medicine-graft-versus-host-disease-gvhd-likelihood-of-approval/ 2025-01-19T18:13:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/maplirpacept-pfizer-acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-likelihood-of-approval/ 2025-01-19T18:13:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ceralasertib-astrazeneca-solid-tumor-likelihood-of-approval/ 2025-01-19T18:13:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pritumumab-nascent-biotech-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:11:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/durvalumab-astrazeneca-pancreatic-cancer-likelihood-of-approval/ 2025-01-19T18:11:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/relatlimab-bristol-myers-squibb-melanoma-likelihood-of-approval/ 2025-01-19T18:11:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ttx-030-trishula-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:50:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/certepetide-lisata-therapeutics-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:50:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nisevokitug-novartis-solid-tumor-likelihood-of-approval/ 2024-09-09T02:01:41+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vobramitamab-duocarmazine-macrogenics-castration-resistant-prostate-cancer-crpc-likelihood-of-approval/ 2025-01-19T17:46:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sasanlimab-pfizer-ovarian-cancer-likelihood-of-approval/ 2024-07-05T05:14:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sasanlimab-pfizer-sarcomas-likelihood-of-approval/ 2024-07-05T05:14:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sasanlimab-pfizer-solid-tumor-likelihood-of-approval/ 2024-07-05T05:14:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-19T17:45:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-19T17:45:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/curcumin-doxorubicin-immix-biopharma-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-09-09T01:59:43+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-19T16:39:06+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lenvatinib-mesylate-eisai-metastatic-biliary-tract-cancer-likelihood-of-approval-2/ 2024-12-25T16:56:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/volrustomig-astrazeneca-cervical-cancer-likelihood-of-approval/ 2025-01-20T16:21:32+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/runimotamab-genentech-usa-solid-tumor-likelihood-of-approval/ 2025-01-20T16:21:28+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imvotamab-igm-biosciences-rheumatoid-arthritis-likelihood-of-approval/ 2025-01-20T16:21:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cadonilimab-akeso-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2025-01-20T16:21:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/sor-007-nanology-metastatic-adenocarcinoma-of-the-pancreas-likelihood-of-approval/ 2025-01-20T16:21:10+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/oleclumab-astrazeneca-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:20:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/luveltamab-tazevibulin-sutro-biopharma-endometrial-cancer-likelihood-of-approval/ 2025-01-20T16:20:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/futibatinib-otsuka-pharmaceutical-solid-tumor-likelihood-of-approval/ 2025-01-20T16:20:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:20:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-20T16:20:05+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-osteosarcoma-likelihood-of-approval/ 2025-01-20T16:20:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-endometrial-cancer-likelihood-of-approval/ 2025-01-20T16:20:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-metastatic-melanoma-likelihood-of-approval/ 2025-01-20T16:19:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-pheochromocytoma-likelihood-of-approval/ 2025-01-20T16:19:53+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-melanoma-likelihood-of-approval/ 2025-01-20T16:19:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/cabozantinib-s-malate-exelixis-colorectal-cancer-likelihood-of-approval/ 2025-01-20T16:19:45+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/baricitinib-eli-lilly-and-co-juvenile-arthritis-likelihood-of-approval/ 2025-01-20T16:19:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/helios-celmod-bristol-myers-squibb-solid-tumor-likelihood-of-approval/ 2024-04-19T17:31:48+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/torl-3600-torl-biotherapeutics-solid-tumor-likelihood-of-approval/ 2025-01-20T16:19:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/adrx-0706-adcentrx-therapeutics-transitional-cell-carcinoma-urothelial-cell-carcinoma-likelihood-of-approval/ 2025-01-20T16:19:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fx-909-flare-therapeutics-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval/ 2024-04-19T17:31:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/fx-909-flare-therapeutics-solid-tumor-likelihood-of-approval/ 2024-04-19T17:31:00+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/snp-318-scineuro-pharmaceuticals-alzheimer-s-disease-likelihood-of-approval/ 2024-01-08T18:36:30+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/askg-915-askgene-pharma-transitional-cell-cancer-urothelial-cell-cancer-likelihood-of-approval/ 2025-01-20T16:18:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/vmt-a-net-perspective-therapeutics-medullary-thyroid-cancer-likelihood-of-approval/ 2025-01-20T16:18:52+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2024-07-05T06:28:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-07-05T06:28:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-07-05T06:28:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-07-05T06:28:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-solid-tumor-likelihood-of-approval/ 2024-07-05T06:28:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bdc-3042-bolt-biotherapeutics-head-and-neck-cancer-likelihood-of-approval/ 2024-07-05T06:28:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/rmc-9805-revolution-medicines-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2025-01-20T16:18:24+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brigimadlin-boehringer-ingelheim-international-metastatic-biliary-tract-cancer-likelihood-of-approval/ 2025-01-20T16:18:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/brigimadlin-boehringer-ingelheim-international-soft-tissue-sarcoma-likelihood-of-approval/ 2025-01-20T16:17:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imvotamab-igm-biosciences-systemic-lupus-erythematosus-likelihood-of-approval/ 2025-01-20T16:17:49+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-metastatic-colorectal-cancer-likelihood-of-approval/ 2025-01-20T16:17:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/toripalimab-shanghai-junshi-biosciences-cervical-cancer-likelihood-of-approval/ 2025-01-20T16:17:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/trastuzumab-deruxtecan-daiichi-sankyo-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval/ 2025-01-20T16:16:56+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-chronic-myelomonocytic-leukemia-cmml-likelihood-of-approval/ 2025-01-20T16:16:47+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-relapsed-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T16:16:44+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-refractory-acute-myeloid-leukemia-likelihood-of-approval/ 2025-01-20T16:16:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/spartalizumab-novartis-myelodysplastic-syndrome-likelihood-of-approval/ 2025-01-20T16:16:38+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/nktr-255-nektar-therapeutics-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T16:16:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/efgartigimod-alfa-argenx-idiopathic-inflammatory-myopathy-iim-likelihood-of-approval/ 2025-01-20T16:16:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-human-epidermal-growth-factor-receptor-2-positive-breast-cancer-her2-breast-cancer-likelihood-of-approval/ 2025-01-20T16:16:23+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/atezolizumab-f-hoffmann-la-roche-breast-cancer-likelihood-of-approval/ 2025-01-20T16:16:19+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ficlatuzumab-aveo-pharmaceuticals-oropharyngeal-cancer-likelihood-of-approval/ 2025-01-20T16:16:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tolimidone-melior-pharmaceuticals-i-type-2-diabetes-likelihood-of-approval/ 2025-01-20T16:16:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/naronapride-renexxion-corrosive-esophagitis-erosive-esophagitis-likelihood-of-approval/ 2025-01-20T16:16:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ozempic-novo-nordisk-chronic-kidney-disease-chronic-renal-failure-likelihood-of-approval/ 2025-01-20T16:15:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pln-101095-pliant-therapeutics-solid-tumor-likelihood-of-approval/ 2025-01-20T16:15:36+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/imsa-101-immunesensor-therapeutics-solid-tumor-likelihood-of-approval-2/ 2024-12-25T18:13:37+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/ph-762-phio-pharmaceuticals-metastatic-melanoma-likelihood-of-approval/ 2025-01-20T02:16:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/danvilostomig-systimmune-gastric-cancer-likelihood-of-approval-2/ 2024-12-25T18:13:13+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-recurrent-glioblastoma-multiforme-gbm-likelihood-of-approval-2/ 2024-12-25T18:11:02+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pegargiminase-polaris-pharmaceuticals-gliosarcoma-likelihood-of-approval-2/ 2024-12-25T18:10:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/lurbinectedin-jazz-pharmaceuticals-metastatic-transitional-urothelial-tract-cancer-likelihood-of-approval-2/ 2024-12-25T18:10:54+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/talimogene-laherparepvec-amgen-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-her2-breast-cancer-likelihood-of-approval-2/ 2024-12-25T18:07:15+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/tocilizumab-chugai-pharmaceutical-follicular-lymphoma-likelihood-of-approval-2/ 2024-12-25T18:07:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/zibotentan-astrazeneca-microvascular-angina-likelihood-of-approval/ 2024-07-05T06:09:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-triple-negative-breast-cancer-tnbc-likelihood-of-approval/ 2025-01-20T02:10:25+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-merkel-cell-carcinoma-likelihood-of-approval/ 2025-01-20T02:10:21+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval/ 2025-01-20T02:10:17+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-nasopharyngeal-cancer-likelihood-of-approval/ 2025-01-20T02:10:12+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-esophageal-cancer-likelihood-of-approval/ 2025-01-20T02:10:08+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-non-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-20T02:10:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-endometrial-cancer-likelihood-of-approval/ 2025-01-19T18:28:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-solid-tumor-likelihood-of-approval/ 2025-01-19T18:28:04+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-small-cell-lung-cancer-likelihood-of-approval/ 2025-01-19T18:27:59+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-gastric-cancer-likelihood-of-approval/ 2025-01-19T18:27:55+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/bgb-30813-beigene-cervical-cancer-likelihood-of-approval/ 2025-01-19T18:27:50+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/amivantamab-johnson-johnson-gastroesophageal-ge-junction-carcinomas-likelihood-of-approval-2/ 2024-12-25T18:04:27+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/pembrolizumab-merck-metastatic-liver-cancer-likelihood-of-approval-2/ 2024-12-25T18:03:58+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-esophageal-squamous-cell-carcinoma-escc-likelihood-of-approval/ 2024-04-19T16:58:46+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-metastatic-castration-resistant-prostate-cancer-mcrpc-likelihood-of-approval/ 2024-04-19T16:58:42+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-epithelial-ovarian-cancer-likelihood-of-approval/ 2024-04-19T16:58:39+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-peritoneal-cancer-likelihood-of-approval/ 2024-04-19T16:58:35+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-metastatic-ovarian-cancer-likelihood-of-approval/ 2024-04-19T16:58:33+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-metastatic-colorectal-cancer-likelihood-of-approval/ 2024-04-19T16:58:29+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-pancreatic-ductal-adenocarcinoma-likelihood-of-approval/ 2024-04-19T16:58:26+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-fallopian-tube-cancer-likelihood-of-approval/ 2024-04-19T16:58:22+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-thyroid-cancer-likelihood-of-approval/ 2024-04-19T16:58:20+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-non-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-19T16:58:16+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-endometrial-cancer-likelihood-of-approval/ 2024-04-19T16:58:14+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-solid-tumor-likelihood-of-approval/ 2024-04-19T16:58:09+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-sarcomas-likelihood-of-approval/ 2024-04-19T16:58:07+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-metastatic-melanoma-likelihood-of-approval/ 2024-04-19T16:58:03+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-small-cell-lung-cancer-likelihood-of-approval/ 2024-04-19T16:58:01+00:00 daily 0.2 https://www.pharmaceutical-technology.com/data-insights/mhb-088c-minghui-pharmaceutical-shanghai-metastatic-hepatocellular-carcinoma-hcc-likelihood-of-approval/ 2024-04-19T16:57:57+00:00 daily 0.2